CLS_B: Revenue up 43% and operating loss halved as CLS accelerates neurosurgery commercialization

About this update from Clinical Laserthermia Systems Ab Class B

Net sales rose 43% year-over-year to SEK 4.5 million, with operating loss halved and strong equity ratio. Strategic financing and regulatory milestones support accelerated commercialization in neurosurgery. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Clinical Laserthermia Systems Ab Class B